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injury worldwide, it is found that the mechanism of cell transplantation repairing
spinal cord injury is mainly to replace damaged neurons, protect host neurons, prevent
apoptosis, promote axonal regeneration and synapse formation, promote myelination,
and secrete trophic factors or growth factors to improve microenvironment. A variety
of cells are used to repair spinal cord injury. Stem cells include multipotent stem
cells, embryonic stem cells, and induced pluripotent stem cells. The multipotent stem
cells are mainly various types of mesenchymal stem cells and neural stem cells.
Non-stem cells include olfactory ensheathing cells and Schwann cells. Transplantation
of inhibitory interneurons to alleviate neuropathic pain in patients is receiving
widespread attention. Different types of cell transplantation have their own advantages
and disadvantages, and multiple cell transplantation may be more helpful to the
patient’s functional recovery. These cells have certain effects on the recovery of
neurological function and the improvement of complications, but further exploration
is needed in clinical application. The application of a variety of cell transplantation,
gene technology, bioengineering and other technologies has made the prospect of
cell transplantation more extensive. There is a need to find a safe and effective
comprehensive treatment to maximize and restore the patient’s performance.

1

Introduction

Spinal cord injury (SCI) is one of the most serious
central nervous system injuries. Most SCI patients
cannot take care of themselves, which brings huge
medical burden to their families and the society. The
incidence of SCI in the world is about 3.6~195.4 per
million [1], which is higher in males than in females,
and mostly are thorax or cervix related [2–6].
There are two main kinds of spinal cord injury. One
is the primary injury, including neural cell damage
and vascular destruction. The other is the secondary
injury, including inflammation, excitotoxicity, edema,
ischemia, chronic demyelination and the formation of
Corresponding author: Fangyong Wang, Email: wfybeijing@163.com

glial scars, etc., causing apoptosis and leading to
increased damage [7, 8].
Surgical interventions, medication, symptomatic
treatments, and hypothermia have been studied and
applied to the treatment of SCI [9], but these methods
are not effective in improving prognosis. Cell therapy
can enhance the endogenous regeneration ability
of spinal cord, which is attracting more and more
attention [10]. 

2

The mechanism and method of cell
transplantation

Cell transplantation therapy for spinal cord injury
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refers to transplanting cells into SCI patients by
local direct transplantation, transvascular grafting or
intrathecal injection for lumbar puncture transplantation
to treat motor, sensory and autonomic dysfunction or
complications caused by SCI. The repair mechanisms
mainly include replacing the damaged neurons,
protecting the host neurons, preventing apoptosis,
promoting axonal regeneration, promotes myelination
and synapse formation, or secreting nutrient factors
to improve microenvironment [11–13]. Different
transplantation methods have their own advantages
and disadvantages. The most widely used method is
the local transplantation, which is the most effective
but also the most invasive, while the vascular
transplantation is opposite [11, 12, 14]. It is generally
believed that the optimal time for cell therapy is
within 2~4 weeks after trauma. Transplantation of
spinal cord injury microenvironment is not conducive
to cell survival and function when conducted prior to
2 weeks, or to the self-recovery of spinal cord function
after 4 weeks [15]. The cells for SCI repair can be
fundamentally categorized as stem and non-stem cells.
The stem cells include pluripotent adult stem cells,
embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs). The non-stem cells include olfactory
ensheathing cells (OECs), Schwann cells and inhibitory
interneurons.

3

Stem cell transplantation

3.1

Pluripotent adult stem cells

The pluripotent adult stem cells for spinal cord injury
mainly include bone marrow-derived mesenchymal
stem cells (BMSCs), umbilical cord blood mesenchymal
stem cells (UCB-MSCs), amniotic fluid-derived
mesenchymal stem cells (AF-MSCs), adipose-derived
mesenchymal stem cells (ADMSCs), oligodendrocyte
precursor cells (OPCs) and neural stem/progenitor
cells (NSPCs), etc.
Mesenchymal stem cells (MSCs) are the most
widely used stem cells in pluripotent adult stem cells,
and mostly exist in bone marrow, fat and pericarpal
tissues (such as cord blood, amniotic membrane,
placenta, etc.). MSCs can secrete a variety of growth
factors, cytokines and neurotrophic factors, which
improve the spinal cord microenvironment [16],

regulate immune response, support hematopoiesis,
inhibit excessive inflammatory response, promote
angiogenesis and tissue repair, anti-scarring tissue
proliferation, anti-apoptosis, anti-inflammatory, and
promote endogenous stem/progenitor cell proliferation
and axonal growth [17, 18].
3.1.1 Bone marrow-derived mesenchymal stem cells
(BMSCs)
As the most commonly used MSCs, BMSCs are easy
to isolate, culture and genetically transduce [17, 18].
Orthotopic transplantation is the major method used
in preclinical experiments [19]. Jung et al. [20] compared
the effects of autologous and allogeneic transplantation
of BMSCs in dogs, and found that both methods can
promote the functional recovery of SCI. Although
autologous BMSCs transplantation can avoid immune
rejection and graft-versus-host reaction in allogeneic
transplantation, it is difficult to apply autologous
stem cell transplantation in clinic because it takes too
long from cell acquisition to cell transplantation [20].
3.1.2 Umbilical cord blood mesenchymal stem cells
(UCB-MSCs)
Umbilical cord blood stem cells have self-renewal and
multi-differentiation potential, and the UCB-MSCs
are the most widely used. UCB-MSCs are easy to
proliferate and culture in vitro, and have good tolerance
to animals and low risk of graft-versus-host disease
after transplantation [21]. Studies have shown that
the repair mechanisms of UCB-MSCs in SCI model
include neurotrophy, anti-inflammatory, anti-apoptosis,
angiogenesis, reduction of glial scar formation and
chemotaxis [22], rather than differentiation into neurons
[17]. UCB-MSCs have relatively fewer ethical controversies and a broader therapeutic potential than
BMSCs [23].
3.1.3 Amniotic fluid-derived mesenchymal stem cells
(AF-MSCs)
AF-MSCs are derived from the amniotic membrane
and amniotic fluid of the embryos, which protect
embryos and help maintaining proper development
of fetal organs, and are usually discarded after
childbirth. Except for the characteristics of MSCs, AFMSCs have unique traits such as non-tumorigenicity
and low immunogenicity, for which AF-MSCs are
widely used in regenerative medicine [24].
Journal of Neurorestoratology
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3.1.4 Adipose-derived mesenchymal stem cells (ADMSCs)
ADMSCs have a wide range of sources, and are easily
acquired and cultured without ethical issues [25].
ADMSCs and BMSCs have similar properties and
play important roles in promoting angiogenesis,
wound healing, reducing inflammatory response and
activating lymphocyte proliferation, and thus more
and more clinical studies has applied ADMSCs transplantation to treating SCI. ADMSCs accumulates in
the injured spinal cord through vein grafting, then
activate cytokines and accelerate the recovery of motor
function and tissue repair in rats [25]. Hur et al. [26]
performed intrathecal autologous transplantation of
ADMSCs in 14 patients with SCI, no serious adverse
events were found during 8 months of follow-up,
and some patients exhibited slight neurological
improvement. Despite this, further verification of
the safety and efficacy of this kind of cell therapy is
needed.
3.1.5

Oligodendrocyte precursor cells (OPCs)

OPCs are a subpopulation of nerve cells that account
for 5%~8% of central nervous system cells. They respond
quickly after injury and proliferate fast, which makes
them a potential source of oligodendrocyte replacement
after SCI. Although effective oligodendrocyte replacement
and adequate remyelination can significantly improve
neurological function, endogenous remyelination is
very difficult after trauma because of the adverse
microenvironment and inflammatory changes after
SCI [27, 28]. A clinical trial of patients with complete
thoracic SCI has shown that transplantation of human
embryonic stem cell-derived oligodendrocyte progenitor
cell therapy product does not cause any adverse clinical
observations, toxicity, allodynia or tumors, which
suggests that OPC is also a good candidate [29].
3.1.6

Neural stem/progenitor cells (NSPCs)

NSPC, which is an ideal candidate for SCI
transplantation, are derived from immature cells in
the nervous system. NSPCs have high ability in selfrenewal duplication, and can migrate to the injury
sites after transplantation. Compared with other stem
cells, their unique advantage is that they can differentiate
and regenerate to functional neurons, and suffer from
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low tumorigenic risk.
NSPCs can significantly improve the functional
recovery of the animal spinal cord transection and
contusion models. Immediate transplantation of NSPCs
after SCI to the mice showed a better effect than
transplantation 35 days later [30]. Different transplant
pathways have different effects. Cheng et al. [31]
transplanted human NSPCs into a rat contusion
model and found that distal transplantation improved
functional recovery in rats, but no significant functional
recovery was seen in orthotopic transplantation. Some
researchers have also explored the safety of NSPCs
transplantation. Curtis et al. [32] had transplanted
human spinal cord neural stem cells (NSI-566) into
4 patients with chronic SCI, and observed no serious
adverse reactions during 18~27 months after transplantation, 2 patients even showed 1~2 levels of
functional improvement.
3.2

Embryonic stem cells (ESCs)

ESCs can be induced and differentiate into neural
stem cells, which are able to differentiate into neurons
and glia. The initial agreement from multiple clinical
trials has been reached, that is, human ESC-based
therapies are safe and promising [33]. Although
embryonic stem cells are the best candidates in theory,
their application potential is limited by sources of
origin, ethical issues, and potential tumorigenic risks
[17, 34, 35]. Studies have also shown that regenerative
axons cannot cross the injury sites, thus they have
limited recovery effects on nerve function [36].
3.3

Induced pluripotent stem cells (iPSCs)

The iPSCs can be obtained from patients themselves
without ethical and immunological rejection problems
[35]. Its therapy mechanism is similar to those of other
cells [37]. It is generally believed that cells which
survive after transplantation can differentiate into
mature neurons and integrate into the host’s neural
pathways, reducing the extent of lesions and promoting
angiogenesis to improve SCI in rat models [38].
However, this technology may cause uncontrolled
cell proliferation and tumor formation risks, and not
all iPSCs transplantation studies have yielded beneficial
results [35].
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4

Non-stem cell transplantation

4.1

Olfactory ensheathing cells (OECs)

Compared with other cells, OECs can migrate long
distance in the central nervous system, making
regenerative axons to get through the interface between
the graft and the host, so they may be the “most
promising candidate cell” [39, 40]. OECs can relieve
neuropathic pain and improve sensory function
caused by SCI [41]. However, the efficacy and safety of
the cell transplantation application is still controversial,
and the ethical problems of olfactory ensheathing cell
transplantation from the embryonic olfactory bulb
still exist.
4.2

Schwann cells

Schwann cells are autologous cells with low immunogenicity and can grow well after transplantation.
Schwann cells can secrete a variety of neurotrophic
factors and growth factors. These factors can nourish
and protect intact nerve cells, promote axonal
regeneration and regenerate axonal myelination, and
reduce spinal cord regeneration disorders [42]. Clinical
trials have shown that transplantation of autologous
Schwann cells into patients with subacute SCI is safe
and has significant therapeutic potential and prospects
[43]. The problems to be solved are their short survival
period and the limited migration distance [42].
4.3

Inhibitory interneurons

Neuropathic pain (NP) is a chronic debilitating disease
caused by neurodegeneration after SCI, and about
59% of SCI patients may experience such chronic
pain [16]. Although there are a variety of drugs used
in the treatment of SCI-NP, their medical effect is not
optimistic, and the side effects are inevitable [44, 45].
Cell therapy can alleviate the mechanical hypersensitivity reaction in rodents and alleviate SCI-NP,
which brings a new idea for the treatment of
SCI-NP [44].
Neuropathic pain may be the result of hypersensitivity to nociceptive neurons induced by increased
neurotrophic factors and neuroinflammation, spinal
cord structural reorganization and inhibition of
interneuronal loss [46]. Medial ganglionic eminence

(MGE) cells and GABAergic interneurons can complement inhibitory interneurons, restore GABAergic
neuron function, inhibit mechanical hypersensitivity,
and improve pain symptoms in patients. MGE is
located in the ventral lateral ventricular wall of the
brain and consists of many types of precursor cells.
GABA precursor cells, the main source of GABAergic
intermediate neurons in cortex and hippocampus,
account for the majority [47]. When transplanted
into the spinal cord of mice model and migrate to
the injured site and differentiate into GABAergic
interneurons and oligodendrocytes, MGE cells integrate
with the host spinal cord to normalize the mechanical
threshold and alleviate the SCI-NP [48, 49]. Howere,
this treatment does not alleviate the pain caused by
the chemical damage model [48].
Although MGE progenitor cells and interneuron-like
cells have been produced from mouse and human
stem cells, little is known about the way to reduce
tumorigenesis, the time it takes to function after
transplantation, or the long-term effects after transplantation [14]. Experiment on larger animal models
is also rare.

5

Trends in cell therapy

As mentioned above, there are many limitations in
the transplantation of only one type of cell. In order
to improve the survival rate of transplanted cells and
maximize their effect, the application of gene therapy,
bioengineered scaffolds and drugs, and multiple cell
transplantation are increasingly gaining the attention
and recognition of researchers. The key to elevating
these methods is to establish a good interaction
environment between cells, scaffolds and bioactive
molecules to promote the repair of damaged tissues
more effectively [14].
5.1 Cell transplantation combined with gene
therapy
The basic strategy of gene therapy for spinal cord
repair is to transcribe specific genes to the site of injury,
creating a good microenvironment [14]. Transgenic
stem cells can not only improve the ability of cells to
differentiate, but also express a large number of specific
neurotrophic factors and reconstruct the spinal nerve
circuit [50]. Many animal SCI model studies combined
Journal of Neurorestoratology
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with gene therapy, such as NT-3 over-secreting BM-SCs
[51] and hUCB-MSCs [52], CSF-induced BM-SCs [53],
Schwann-like cells after BM-SCs being induced by
sciatic nerve fragments [54], etc. They have all been
proved to be better than simply transplanting cell in
promoting functional recovery.
However, gene expression induction in cells often
increases the risk of tumor formation [55]. Before
these therapies can be used in clinical trials, extensive
animal studies are needed to ensure the safety of gene
therapy in combination with cell transplantation.
5.2 Cell therapy combined with tissue engineering
scaffold
Tissue-surgical scaffolds with sufficient tissue compatibility can be used to connect the upper and lower
neuronal pathways and improve the microenvironment,
promote axonal regeneration [56]. Combining with
cell transplantation can increase cell viability and
increase differentiation efficiency, and provide appropriate transfer factors to optimize therapeutic effects
[55, 57, 58]. Many natural and synthetic tissue
engineering scaffolds combined with cell transplantation to treat SCI have achieved certain effects,
such as agarose, sodium alginate, chitosan, collagen,
fibrin, fibronectin, methylcellulose, PGA/PLA/PLGA/
PLCL, matrigel, polyethylene glycol/polyoxyethylene
ether, etc.[11, 19, 58]. Some new technologies also
bring opportunities to the treatment of SCI, such as
biomimetic 3D-printed scaffolds [59].
The perfect combination of tissue engineering
materials and stem cells is not easy to achieve, and
more research will be done in the future to create ideal
tissue engineering scaffolds that allow transplanted
cells to migrate into the host spinal cord tissue, while
nerve cells and axons from the host spinal cord tissue
can grow into the stent to maximize the motor function
of patients with SCI [56].
5.3 Combined transplantation of different type of
cells
By combining different type of cells in transplantation,
it is possible to exert complementary effects by
utilizing their respective physiological characteristics.
There are many studies suggesting that different types
of stem cell combinations can repair the spinal cord
more effectively than single cells during transplantation
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after SCI [60]. Because different types of cells may
secrete different neurotrophic factors and promote
axonal regeneration in the injured area [56].
Instead of simply increasing the number of nerve
cells, increasing the secretion of neurotrophic substances,
promoting the growth of damaged axons, angiogenesis,
adjusting the balance between pro-apoptotic factors
and anti-apoptotic factors, and reducing the volume
of damaged tissues are increasingly used in animal
experiments and clinical trials. More and more attention
has been paid to the cell transplantation therapy
of SCI [60]. While more research is still needed to
determine the optimal combination of different stem
cell types, numbers, and densities to achieve optimal
functional recovery after SCI.

6

Summary and outlook

Cell therapy provides us with a new way to restore
the function of SCI patients, but there are inevitably
many problems. Research on cell repair of SCI is still
at the primary stage and restrained to animal models,
and current literature and clinical studies have not
provided evidence for safe and effective consistency
of this method. Despite the advances in molecular
biology and cell detection techniques, the genetic
stability of transplanted cells remains elusive, and
potential cancer risk, autophagy, and promotion of
tumor growth and viral transmission require further
study [61]. The influencing factors in cell therapy for
SCI include SCI model, cell source, dose, differentiation
and transplantation time, transplantation route, etc.
[37, 40], which make the results of most studies
difficult to compare with each other. This leads to a
different prognosis even for the same trial method
[62]. There are animal or preclinical trials on cell
transplantation for cervical SCI, which accounts for a
large proportion of SCI morbidity [35]. The human
nervous system, behavioral performance and biological
difference, long-term effects after cell transplantation
cannot be simulated or rigorously tested in animal
experiments [46], so cell therapy is not currently used
in clinical practice. For complete SCI, how to improve
its limb function most effectively is also a huge
challenge. There are no optimal protocols for different
types and courses of SCI, and more preclinical studies
will be needed in terms of cell preparation, cell type
and number, and timing and route of administration.
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At the same time, more clinical trials of evidencebased medical evidence are needed [63]. Most of the
experimental studies have focused on the recovery
of motor function in rats, with less attention to other
dysfunctions such as neuropathic pain, bladder
dysfunction, and spasm [64].
Finding a safe, appropriate, efficient and comprehensive treatment method will be the direction for
future research. This requires international multi-center
collaborative clinical trials to enable comparative
analysis in more and more homogeneous patient
populations, and accelerated transition of clinical
trials into clinical applications. With the exploration
of the molecular mechanisms of nerve regeneration
of SCI in animal models and clinical environments,
as well as the development of genetic and tissue
engineering techniques, the prospect of cell repair of
SCI will be even broader.
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